Transcriptome Profiling of Acquired Gefitinib Resistant Lung Cancer Cells Reveals Dramatically Changed Transcription Programs and New Treatment Targets

Background: Targeted therapy for lung cancer with epidermal growth factor receptor (EGFR) mutations with tyrosine kinase inhibitors (TKIs) represents one of the major breakthroughs in lung cancer management. However, gradually developed resistance to these drugs prevents sustained clinical benefits...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Nan, Song, Yong'an, Zhang, Fan, Sun, Zhifu, Zhang, Xiaoju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456826/
https://www.ncbi.nlm.nih.gov/pubmed/32923394
http://dx.doi.org/10.3389/fonc.2020.01424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456826/
https://www.ncbi.nlm.nih.gov/pubmed/32923394
http://dx.doi.org/10.3389/fonc.2020.01424

Ejemplares similares